ARTICLE | Company News
Tyg and Cancer Research UK (CRUK) partnered to develop Tyg’s TYG100. CRUK will conduct a Phase I trial of TYG100 to treat solid tumors. Upon completion of the trial, Tyg will have the option to retain...
BCIQ Target Profiles
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Tyg and Cancer Research UK (CRUK) partnered to develop Tyg’s TYG100. CRUK will conduct a Phase I trial of TYG100 to treat solid tumors. Upon completion of the trial, Tyg will have the option to retain...
BCIQ Target Profiles